Disseminated Inflammatory Lesions in 2 Patients With COVID-19: Answer

Fernández‐Figueras, María‐Teresa; Moreno, Juan Antonio; Pérez-Muñoz, Noelia; Herranz, Xavier; Maynard, Avonello; Sánchez-Sitjes, Lluís; Sánchez, A.

doi:10.1097/dad.0000000000001778

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, two cases of inflammatory DSP associated with COVID‐19 infection were reported. The authors postulate that COVID‐19 infection may have triggered an immune response that led to the intensification of the inflammatory reaction against the mutated clones of keratinocytes from pre‐existing DSP lesions 6 . Similarly, we speculate that COVID‐19 mRNA vaccination might have triggered an immune response against mutated clones of keratinocytes in the present case, as in COVID‐19 infection.…”

Section: Discussionsupporting

confidence: 55%

Exacerbation of inflammatory disseminated superficial porokeratosis following COVID‐19 vaccination

Ishikawa

Asai

Katoh

2023

JEADV Clinical Practice

View full text Add to dashboard Cite

The mRNA‐1273 vaccine for coronavirus disease (COVID‐19) authorised as one of the first COVID‐19 vaccines was released by Moderna in December 2020. A recent study indicates that messenger RNA (mRNA) vaccines appear to be effective in preventing aggravation, hospitalisation and death against COVID‐19 infection. However several adverse effects have been reported. Of these, the dermatological adverse effects are relatively rare entities Herein, we present a case of inflammatory disseminated superficial porokeratosis exacerbated after administration of the fourth dose of the mRNA‐1273 vaccine.

show abstract

Section: Discussionsupporting

confidence: 55%

Exacerbation of inflammatory disseminated superficial porokeratosis following COVID‐19 vaccination

Ishikawa

Asai

Katoh

2023

JEADV Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Attributed to molecular mimicry and upregulated inflammatory, immunological pathways, it has been postulated that COVID-19 vaccines might contribute to immune-mediated phenomena, either exacerbating the preexisting or new onset of immune-mediated disorders. 17 In consistency with initial considerations in support of an immunological response against abnormal clones of keratinocytes as the underlying cause of eruptive pruritic papular porokeratosis, 13,14 Fernandez-Figueras et al 18,19 postulated that COVID-19 infection might have triggered an immune response related to the intensification of an inflammatory reaction against mutated clones from preexisting porokeratotic lesions.…”

Section: Discussionmentioning

confidence: 82%

Eruptive Pruritic Maculopapular Rash Following Pfizer-BioNTech COVID-19 Vaccination: Answer

Maierhofer,

Dhirad,

Papathomas

2023

The American Journal of Dermatopathology

View full text Add to dashboard Cite

“…In addition, some patients develop flares of non-autoimmune dermatitis such as inflammatory porokeratosis [ 17 ] and other conditions. Conversely, cutaneous drug reactions are not especially frequent in COVID-19 patients [ 18 ] and the use of personal protective equipment leads to only mild problems.…”

Section: Other Cutaneous Alterations Related To Covid-19 Infectionmentioning

confidence: 99%

Dermatopathology of COVID-19 infection and vaccination

Fernández‐Figueras

2022

Pathologie

View full text Add to dashboard Cite

Background Many peculiar skin changes have been described in relation to both coronavirus disease 2019 (COVID-19) infection and vaccination. Objective This paper provides an overview of these dermatologic manifestations, focusing on their dermatopathological appearances. Results Most COVID-19 patients develop variegated maculopapular eruptions with a combination of histological patterns commonly including keratinocyte apoptosis and eosinophilia. Urticaria-like lesions often show a combination of spongiotic and lichenoid patterns and are more frequent in individuals with severe disease. Vesicular lesions can be disseminated; in some cases, they become pustular and in others show dyskeratosis and a peculiar form of ballooning. Some patients develop vesicular Grover disease on the trunk. Young patients with a strong immunological response can eliminate the virus easily but may develop chilblains as a consequence of the high interferon response. Conversely, older individuals with immunosenescence and a tendency toward hypercoagulability can present livedoid and ischemic areas. Regarding COVID-19 vaccination, hypersensitivity reactions are most frequent, including “COVID-arm.” Nonetheless, a combination of local and systemic cutaneous manifestations (reactogenicity) is commonly seen. Histopathologically, lichenoid and spongiotic changes and a variable number of eosinophils are typical of rashes characterized by papules and plaques. Other dermatological side effects of COVID-19 vaccination include lesions mimicking well-defined dermatoses such as lichen planus or bullous pemphigoid and triggering of collagenous diseases. Conclusion Well-characterized skin manifestations of coronavirus disease 2019 (COVID-19) include chilblains, livedo necrotic lesions, vesicular eruptions, urticarial lesions, and maculopapular eruptions. Hypersensitivity reactions are common after SARS-CoV‑2 mRNA vaccination. Vaccine reactions may also mimic other dermatosis such as bullous pemphigoid or lichen planus, stimulate herpes reactivation, or trigger the development of autoimmune diseases.

show abstract

Disseminated Inflammatory Lesions in 2 Patients With COVID-19: Answer

Cited by 3 publications

References 10 publications

Exacerbation of inflammatory disseminated superficial porokeratosis following COVID‐19 vaccination

Exacerbation of inflammatory disseminated superficial porokeratosis following COVID‐19 vaccination

Eruptive Pruritic Maculopapular Rash Following Pfizer-BioNTech COVID-19 Vaccination: Answer

Dermatopathology of COVID-19 infection and vaccination

Contact Info

Product

Resources

About